Name (Synonyms) | Correlation | |
---|---|---|
drug279 | Cambridge Validated Viral Detection Method Wiki | 1.00 |
drug1124 | Radiological Detection Wiki | 1.00 |
drug1017 | Placebo (PBO) Wiki | 1.00 |
drug1178 | SAMBA II (Diagnostic for the Real World) Wiki | 1.00 |
drug1089 | Public Health England Gold Standard Wiki | 1.00 |
drug15 | 200 mg EIDD-2801 Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D000208 | Acute Disease NIH | 1.00 |
D014777 | Virus Diseases NIH | 0.13 |
D018352 | Coronavirus Infections NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Designed as a single center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction (PCR)-Confirmed COVID-19.
Description: Achievement of undetectable SARS-CoV-2 RNA by Day 5 in nasopharyngeal (NP) swabs by quantitative reverse transcription polymerase chain reaction (qPCR) after administration with EIDD-2801
Measure: Number of Participants that achieve Virologic Clearance after oral administration of EIDD-2801 Time: 28 daysDescription: Incidence of Serious Adverse Events in subjects receiving EIDD-2801
Measure: Number of Participants With any Serious Adverse Events(SAEs) as assessed by DAIDS Time: 28 daysDescription: Incidence of Adverse Events in subjects receiving EIDD-2801
Measure: Number of Participants With any Adverse Events(AEs) as assessed by DAIDS Time: 28 days